SCHEMBL27682003

SCHEMBL27682003

O=C(O)C(CCCO)c1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 4/20 0.43
ACP3 P15309 3/20 0.42
ECE1 P42892 1/20 0.42
CYP1A2 P05177 1/20 0.41
EPHX2 P34913 2/20 0.40
SLC6A4 P31645 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842064 0.86 ALOX5 (0.44) CYP2C9CYP2C19HPGDHTTALDH1A1
SCHEMBL729984 0.86 CYP2C19 (0.47) CYP2C9CYP2C19HPGDHTTALDH1A1
SCHEMBL1533601 0.86 CYP2C9 (0.43) CYP2C9CYP2C19HPGDHTTALDH1A1
SCHEMBL18259143 0.85 CYP2C19 (0.46) CYP2C9CYP2C19HPGDHTTALDH1A1
Adipic Acid SCHEMBL1866364 0.85 CYP2C19 (0.46) CYP2C9CYP2C19HPGDHTTALDH1A1
SCHEMBL5156697 0.85 KDM4E (0.47) CYP2C9CYP2C19HPGDHTTEPHX2
SCHEMBL451183 0.84 KDM4E (0.49) CYP2C9CYP2C19HPGDHTTEPHX2
SCHEMBL1826965 0.84 KDM4E (0.49) CYP2C9CYP2C19HPGDHTTEPHX2
SCHEMBL8015861 0.84 KDM4E (0.49) CYP2C9CYP2C19HPGDHTTEPHX2
SCHEMBL2024342 0.84 KDM4E (0.49) CYP2C9CYP2C19HPGDHTTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1972920-A Arylalkyl piperazine derivatives for the treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms WYETH CORP (US) 2007-05-30 CN disclosed